The FDA granted 510(k) clearance to Motivista, a prescription digital therapeutic developed by Click Therapeutics, as an adjunctive treatment for adults with negative symptoms of schizophrenia.
Agree
Disagree
Overview
Debates
Related claims
Topics
Sources
From the article
FDA clears Motivista for negative symptoms in schizophrenia
Also in
Pill Peddling Doc Convicted; Digital Schizophrenia Therapeutic Cleared; AI Anxiety
5
52c7ae14
Article
FDA clears Motivista for negative symptoms in schizophrenia
0
5
52c7ae14
Article
Pill Peddling Doc Convicted; Digital Schizophrenia Therapeutic Cleared; AI Anxiety
0